Artificial antigen-presenting cell

Artificial antigen presenting cells (aAPCs) are engineered platforms designed to mimic the function of natural antigen-presenting cells (APCs) in stimulating T-cell responses. They are an emerging technology in cancer immunotherapy, which aims to harness the immune system to recognize and eliminate mutated cancer cells in a manner similar to how the body defends against viruses and other infectious agents.

Natural APCs act as sentinels of the immune system, patrolling the body for pathogens. When a pathogen is encountered, these cells activate T cells—often described as the "soldiers" of the immune system—by delivering specific stimulatory signals via cell surface molecules (epitopes). aAPCs replicate this process synthetically by attaching T-cell-activating signals to biocompatible surfaces, such as micron-sized beads or other macro- and microscale materials.

By imitating the antigen-presenting function of natural APCs, aAPCs allow for controlled activation and expansion of functional, pathogen- or tumor-specific T cells. These activated T cells can be studied in a biomimetic context and used for adoptive cell transfer therapies. aAPCs also offer potential advantages over natural APCs, including scalable production, lower cost, and enhanced experimental control.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.